Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: A pilot study
Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: A pilot study
复制标题
DOI：
10.3233/rnn-2011-0629
复制
发表时间：
2012-01-01
影响因子：
2.8
通讯作者：
Ide, Chizuka
中科院分区：
文献类型：
--
作者：
Saito, Fukuki;Nakatani, Toshio;Ide, Chizuka
目的：为了确定鞘内注射培养的自体骨髓基质干细胞（BMSCs）是否是安全和可行的治疗亚急性脊髓injury.Methods：5例完全性四肢瘫痪，由于颈椎损伤入院。在脊柱融合手术中获得了少量骨髓。培养骨髓间充质干细胞，达到10（7）-10（8）个细胞。BMSCs的特性和功能功效通过表面标记分析和神经突延伸试验进行验证。骨髓间充质干细胞经腰椎穿刺给药。观察6个月，临床治疗有效性和安全性委员会（CESCT）评价其安全性。结果：所有患者均未出现不良反应。CESCT没有认识到移植的任何有害影响，并得出结论认为治疗是安全的。随访1 ~ 4年，无不良反应。美国脊髓损伤协会损伤量表（AIS）B和C级患者移植时恢复迅速而显著，而AIS A级患者移植后恢复缓慢或有限。结论：鞘内注射培养的自体BMSCs治疗脊髓损伤是安全可行的。
Purpose: To determine whether intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs) is safe and feasible for treatment of subacute spinal injury.Methods: Five patients with complete tetraplegia due to cervical spinal injury on admission were included. A small amount of bone marrow was obtained during surgery for spinal fusion. BMSCs were cultured, reaching 10(7)-10(8) cells. The properties and functional efficacy of the BMSCs were verified with surface marker analysis and a neurite extension test. BMSCs were administered by lumbar puncture. The patients were closely observed for 6 months, and the Committee on Effectiveness and Safety of Clinical Treatment (CESCT) evaluated safety.Results: No adverse responses were observed in biochemical and radiographic examinations. The CESCT did not recognize any harmful effects of the transplantation, and concluded it was safe for treatment. The patients were further followed up for 1 to 4 years with no adverse responses. The recovery of American Spinal Injury Association Impairment Scale (AIS) B and C patients at transplantation was rapid and remarkable, but gradual or limited in AIS A patients.Conclusion: This study demonstrated that intrathecal administration of cultured autologous BMSCs is safe and feasible for treatment of spinal cord injury.